Baas DJH, Schilham M, Hermsen R, de Baaij JMS, Vrijhof HJEJ, Hoekstra RJ, et al. Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection. Prostate Cancer Prostat Dis. 2022;25:65–70.

Article  CAS  Google Scholar 

Dekalo S, Kuten J, Mintz I, Fahoum I, Gitstein G, Keizman D, et al. Preoperative 68Ga-PSMA PET/CT defines a subgroup of high-risk prostate cancer patients with favorable outcomes after radical prostatectomy and lymph node dissection. Prostate Cancer Prostat Dis. 2021;24:910–6.

Article  CAS  Google Scholar 

Meyrick DP, Asokendaran M, Skelly LA, Lenzo NP, Henderson A The role of 68Ga-PSMA-I&T PET/CT in the pretreatment staging of primary prostate cancer. Nuclear Medicine Communications [Internet]. 2017;38. Available from: https://journals.lww.com/nuclearmedicinecomm/fulltext/2017/11000/the_role_of_68ga_psma_i_t_pet_ct_in_the.10.aspx.

Emmett et al. 2022 The PRIMARY Score Using intra-prostatic PSMA PET.pdf.

Ditonno F, Franco A, Manfredi C, Veccia A, Valerio M, Bukavina L, et al. Novel non-MRI imaging techniques for primary diagnosis of prostate cancer: micro-ultrasound, contrast-enhanced ultrasound, elastography, multiparametric ultrasound, and PSMA PET/CT. Prostate Cancer Prostatic Dis. 2023.

Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208–16.

Article  CAS  PubMed  Google Scholar 

Mottet N, van den Bergh RCN, Briers E, den Broeck TV, Cumberbatch MG, Santis MD, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021;79:243–62.

Article  CAS  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

Article  PubMed  PubMed Central  Google Scholar 

Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.

Article  PubMed  PubMed Central  Google Scholar 

Brauchli D, Singh D, Chabert C, Somasundaram A, Collie L. Tumour-capsule interface measured on 18F-DCFPyL PSMA positron emission tomography/CT imaging comparable to multi-parametric MRI in predicting extra-prostatic extension of prostate cancer at initial staging. J Med Imaging Radiat. Oncol. 2020;64:829–38.

Article  PubMed  Google Scholar 

Rajwa P, Pfister D, Rieger C, Heidenreich J, Drzezga A, Persigehl T, et al. Importance of magnetic resonance imaging and prostate-specific membrane antigen PET-CT in patients treated with salvage radical prostatectomy for radiorecurrent prostate cancer. Prostate. 2023;83:385–91.

Article  CAS  PubMed  Google Scholar 

Harsini S, Fallahi B, Karamzade Ziarati N, Razi A, Amini E, Emami-Ardekani A, et al. A Prospective Study on [(68)Ga]-PSMA PET/CT Imaging in Newly Diagnosed Intermediate- and High-Risk Prostate Cancer. Asia Ocean J Nucl. Med Biol. 2021;9:101–10.

PubMed  PubMed Central  Google Scholar 

Grubmüller B, Baltzer P, Hartenbach S, D’Andrea D, Helbich TH, Haug AR, et al. PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact. Clin. Cancer Res 2018;24:6300–7.

Article  PubMed  Google Scholar 

Muehlematter UJ, Burger IA, Becker AS, Schawkat K, Hötker AM, Reiner CS, et al. Diagnostic Accuracy of Multiparametric MRI versus (68)Ga-PSMA-11 PET/MRI for Extracapsular Extension and Seminal Vesicle Invasion in Patients with Prostate Cancer. Radiology. 2019;293:350–8.

Article  PubMed  Google Scholar 

Hijazi S, Meller B, Leitsmann C, Strauss A, Meller J, Ritter CO, et al. Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography. Prostate. 2015;75:1934–40.

Article  CAS  PubMed  Google Scholar 

Klingenberg S, Jochumsen MR, Ulhøi BP, Fredsøe J, Sørensen KD, Borre M, et al. (68)Ga-PSMA PET/CT for Primary Lymph Node and Distant Metastasis NM Staging of High-Risk Prostate Cancer. J Nucl Med 2021;62:214–20.

Article  CAS  PubMed  Google Scholar 

Kubilay E, Akpinar Ç, Oǧuz ES, Araz MS, Soydal Ç, Baltacı S, et al. Significance of metabolic tumor volume and total lesion uptake measured using Ga-68 labelled prostate-specific membrane antigen PET/CT in primary staging of prostate cancer. Urol Oncol. 2022;40:408.e19–408.e25.

Article  CAS  PubMed  Google Scholar 

Moreira LF, Mussi TC, Cunha MLda, Filippi RZ, Baroni RH. Accuracy of (68)Ga-PSMA PET/CT for lymph node and bone primary staging in prostate cancer. Urol. Oncol. 2022;40:104.e17–104.e21.

Article  CAS  PubMed  Google Scholar 

Anttinen M, Ettala O, Malaspina S, Jambor I, Sandell M, Kajander S, et al. A Prospective Comparison of 18F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE). Eur Urol Oncol. 2021;4:635–44.

Article  PubMed  Google Scholar 

Lenis AT, Pooli A, Lec PM, Sadun TY, Johnson DC, Lebacle C, et al. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study. Eur. Urol. Oncol. 2022;5:544–52.

Article  PubMed  Google Scholar 

Dyrberg E, Hendel HW, Huynh THV, Klausen TW, Løgager VB, Madsen C, et al. 68Ga-PSMA-PET/CT in comparison with 18F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study. Eur. Radio. 2019;29:1221–30.

Article  Google Scholar 

Lengana T, Lawal IO, Boshomane TG, Popoola GO, Mokoala KMG, Moshokoa E, et al. 68Ga-PSMA PET/CT Replacing Bone Scan in the Initial Staging of Skeletal Metastasis in Prostate Cancer: A Fait Accompli? Clin Genitourin Cancer 2018;16:392–401.

Article  PubMed  Google Scholar 

Zacho HD, Ravn S, Afshar-Oromieh A, Fledelius J, Ejlersen JA, Petersen LJ. Added value of 68Ga-PSMA PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer and a previous 99mTc bone scintigraphy. EJNMMI Res 2020;10:31.

Article  PubMed  PubMed Central  Google Scholar 

Madsen C, Østergren P, Haarmark C. The Value of 68Ga-PSMA PET/CT Following Equivocal 18F-NaF PET/CT in Prostate Cancer Patients. Diagnostics. 2020;10:352.

Mattoni S, Farolfi A, Formaggio F, Bruno G, Caroli P, Cerci JJ, et al. PSMA PET for the Evaluation of Liver Metastases in Castration-Resistant Prostate Cancer Patients: A Multicenter Retrospective Study. Cancers (Basel). 2022;14:5680.

Bauckneht M, Checcucci E, Cisero E, Rizzo A, Racca M, De Cillis S, et al. The prognostic role of next-generation imaging-driven upstaging in newly diagnosed prostate cancer patients. Eur. J. Nucl. Med Mol. Imaging 2024;51:864–70.

Article  CAS  PubMed  Google Scholar 

Hofman MS, Murphy DG, Williams SG, Nzenza T, Herschtal A, Lourenco RDA, et al. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol. BJU Int 2018;122:783–93.

Article  CAS  PubMed  Google Scholar 

Koerber SA, Stach G, Kratochwil C, Haefner MF, Rathke H, Herfarth K, et al. Lymph Node Involvement in Treatment-Naïve Prostate Cancer Patients: Correlation of PSMA PET/CT Imaging and Roach Formula in 280 Men in Radiotherapeutic Management. J Nucl Med 2020;61:46–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chow KM, So WZ, Lee HJ, Lee A, Yap DWT, Takwoingi Y, et al. Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2023;84:36–48.

Article  PubMed  Google Scholar 

Grünig H, Maurer A, Thali Y, Kovacs Z, Strobel K, Burger IA, et al. Focal unspecific bone uptake on [18F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging. Eur J Nucl Med Mol Imaging. 2021;48:4483–94.

Anttinen M, Ettala O, Malaspina S, Jambor I, Sandell M, Kajander S, et al. A Prospective Comparison of (18)F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE). Eur Urol Oncol. 2021;4:635–44.

Article  PubMed  Google Scholar 

Arslan A, Karaarslan E, Güner AL, Sağlıcan Y, Tuna MB, Özışık O, et al. Comparison of MRI, PSMA PET/CT, and Fusion PSMA PET/MRI for Detection of Clinically Significant Prostate Cancer. J Comput Assist Tomogr. 2021;45:210–7.

Article  PubMed  Google Scholar 

Budäus L, Leyh-Bannurah SR, Salomon G, Michl U, Heinzer H, Huland H, et al. Initial Experience of 68Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. Eur. Urol. [Internet] 2016;69:393–6. https://linkinghub.elsevier.com/retrieve/pii/S0302283815005138.

Article  PubMed  Google Scholar 

Barbosa ÁRG, Amaral BS, Lourenço DB, Bianco B, Gushiken FA, Apezzato M, et al. Accuracy of 68Ga-PSMA PET-CT and PET-MRI in lymph node staging for localized prostate cancer. Einstein (Sao Paulo). 2022;20:eAO6599.

Article  PubMed  Google Scholar 

Chen M, Zhang Q, Zhang C, Zhao X, Marra G, Gao J, et al. Combination of (68)Ga-PSMA PET/CT and Multiparametric MRI Improves the Detection of Clinically Significant Prostate Cancer: